This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: Chelsea's FDA Panel, Ariad's Future, Bio-Bubble Update

Study 306B is the new clinical trial, which like Study 301, demonstrated a statistically significant reduction in dizziness. Oliveto believes having positive Northera data from Study 306B that is consistent with Study 301 works in Chelsea's favor. Two positive studies are always better than one. Oliveto is right.

But... Study 306B isn't pristine, so Chelsea will need to explain some of the trial's quirks and inconsistencies. For starters, Study 306B is really a "do over" trial stemming from the failure of Study 306. Study 306B has also undergone at least two major revisions to its statistical analysis plan, including changing the primary endpoint from fall reduction to reduction in dizziness score.

But despite these changes, the conduct of Study 306B was not adversely affected and reduction in dizziness is the signal measure of clinical benefit for the treatment of NOH deemed most important by the agency, Oliveto says.

Fine, makes sense, but let's not be entirely confident until we see what FDA says in the Northera briefing documents.

Another Study 306B issue: The primary endpoint was achieved based on a modified intent-to-treat patient population. Chelsea excluded patients who dropped out of the study during the titration phase. (More patients randomized to Northera dropped out than those on placebo.)

What happens to Study 306B if the most conservative statistical analysis is applied?

"The study loses statistical significance," Oliveto admits.

Before you start to panic, Oliveto argues -- and he has a good point -- the most conservative statistical analysis of Study 306B isn't necessarily the most appropriate analysis. Missing patient data from Study 306B will likely be a topic of discussion at the Jan. 14 panel but Chelsea has performed multiple statistical analyses and is confident that all demonstrate Northera's clinical benefit in this NOH patient population, he says.

Here's another Northera data slide of interest, showing a huge reduction in the number of falls experienced by NOH patients treated with Northera compared placebo. Preventing or reducing falls is obviously important to doctors and NOH patients, so Northera's ability to reduce falls is a positive.

2 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs